Skip to main content

Remote Job Finders (RJF)

Astellas Divorces CytomX Despite Positive Phase 1 Data for Antibody Platform

Astellas Pharma and CytomX Therapeutics first partnered up in March 2020. For $80 million upfront, the Japanese pharma gained access to the biotech’s Probody platform to generate masked antibody therapies for cancer.

Lilly Flags ‘Concerning’ Impurities in Compounded Tirzepatide

Combining tirzepatide with vitamin B12, a common additive in compounded versions of the drug, yields an impurity that could alter the drug’s toxicity profile and pose safety risks to patients, the company said in an open letter.
Scroll to top